Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 5/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454503 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6MAPTKMT2ACYP2C19 | |
| SCHEMBL27570861 | 0.88 | CYP1A2 (0.78) | CYP1A2CYP2D6MAPTKMT2ACYP2C19 | |
| SCHEMBL4989116 | 0.86 | CYP2D6 (0.75) | CYP1A2CYP2D6MAPTKMT2ACYP2C19 | |
| SCHEMBL14944875 | 0.82 | CYP2D6 (0.70) | CYP1A2CYP2D6MAPTKMT2ACYP2C19 | |
| SCHEMBL10607689 | 0.82 | CYP2D6 (0.70) | CYP1A2CYP2D6MAPTKMT2ACYP2C19 | |
| SCHEMBL5307865 | 0.82 | CYP2D6 (0.70) | CYP1A2CYP2D6MAPTKMT2ACYP2C19 | |
| SCHEMBL28636479 | 0.81 | CYP2D6 (0.68) | CYP1A2CYP2D6MAPTKMT2ACYP2C19 | |
| SCHEMBL75956 | 0.81 | CYP1A2 (0.68) | CYP1A2CYP2D6MAPTKMT2ACYP2C19 | |
| SCHEMBL1082430 | 0.81 | CYP1A2 (0.68) | CYP1A2CYP2D6MAPTKMT2AHIF1A | |
| SCHEMBL28463954 | 0.80 | CYP2D6 (0.66) | CYP1A2CYP2D6MAPTKMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851119-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2020-05-21 | — | — | US | disclosed |
| CN-107406373-B | Boron-containing diacylhydrazine compounds | 英特瑞克斯顿股份有限公司 | 2020-04-28 | — | — | CN | disclosed |
| EP-3194359-B1 | BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDS | INTREXON CORP (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10570158-B2 | Boron-containing diacylhydrazine compounds | INTREXON CORPORATION (US) | 2020-02-25 | — | — | US | disclosed |
| US-10464951-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180201628-A1 | Boron-Containing Diacylhydrazine Compounds | INTREXON CORP (US) | 2018-07-19 | — | — | US | disclosed |
| EP-2970106-B1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9944659-B2 | Boron-containing diacylhydrazine compounds | INTREXON CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | INVITROGEN CORPORATION | 2002-10-24 | — | — | US | disclosed |
| EP-1220869-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | Cytovia, Inc. (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2002013848-A1 | HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS | INVITROGEN CORPORATION (US) | 2002-02-21 | — | — | WO | disclosed |
| CN-1297354-A | Dipeptide caspase inhibitors and use thereof | CYTOVIA INC (US) | 2001-05-30 | — | — | CN | disclosed |
| WO-2001027140-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | CYTOVIA, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-1076563-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6153591-A | PROTECTING NERVOUS SYSTEM FOLLOWING FOCAL ISCHEMIA AND GLOBAL ISCHEMIA; ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PRION DISEASES, PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, ALOPACIA, RHEUMATOID ARTHRITIS | CYTOVIA, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999047154-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
| EP-0853626-A1 | SUBSTITUTED PHOSPHINIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Novartis AG (CH) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997009335-A1 | SUBSTITUTED PHOSPHINIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464951-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | CYP1A2 2524/4885CYP2D6 1022/4885MAPT 4167/4885 |
| US-20180201628-A1 | Boron-Containing Diacylhydrazine Compounds | BRDT, CD22, BCR | CYP1A2 2935/4885CYP2D6 1065/4885MAPT 4018/4885 |
| US-10851119-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | CYP1A2 2524/4885CYP2D6 1022/4885MAPT 4167/4885 |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | CD22, BRDT, BCR | CYP1A2 2524/4885CYP2D6 1022/4885MAPT 4167/4885 |
| US-10570158-B2 | Boron-containing diacylhydrazine compounds | BRDT, CD22, BCR | CYP1A2 2935/4885CYP2D6 1065/4885MAPT 4018/4885 |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | CYP1A2 2524/4885CYP2D6 1022/4885MAPT 4167/4885 |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | CD44, HLA-C, HLA-A | CYP1A2 3043/4885CYP2D6 2640/4885MAPT 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.